TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells

Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients

(2013) R. M. Srivastava et al.   CLINICAL CANCER RESEARCH

The impact of Fc-  receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab

(2011) M. Ahlgrimm et al.   BLOOD

VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC

(2011) H. Lu et al.   CLINICAL CANCER RESEARCH

Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity

(2011) Steve C. Lee et al.   IMMUNOLOGIC RESEARCH

Epidermal Growth Factor Receptor (EGFR) Antibody-Induced Antibody-Dependent Cellular Cytotoxicity Plays a Prominent Role in Inhibiting Tumorigenesis, Even of Tumor Cells Insensitive to EGFR Signaling Inhibition

(2011) M. B. Overdijk et al.   JOURNAL OF IMMUNOLOGY

Regulation of Antitumor Immune Responses by the IL-12 Family Cytokines, IL-12, IL-23, and IL-27

(2010) Mingli Xu et al.   Clinical & Developmental Immunology

Tumor Antigen Cross-Presentation and the Dendritic Cell: Where it All Begins?

(2010) Alison M. McDonnell et al.   Clinical & Developmental Immunology

Tumor Antigen–Targeted, Monoclonal Antibody–Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape

(2010) Robert L. Ferris et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells

(2009) Andrés López-Albaitero et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Strong CD8+ T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma

(2009) Kazumasa Hiroishi et al.   JOURNAL OF GASTROENTEROLOGY

Human Dendritic Cells Stimulated via TLR7 and/or TLR8 Induce the Sequential Production of Il-10, IFN- , and IL-17A by Naive CD4+ T Cells

(2009) V. Lombardi et al.   JOURNAL OF IMMUNOLOGY

Novel Immunogenic HLA-A*0201-restricted Epidermal Growth Factor Receptor-specific T-cell Epitope in Head and Neck Cancer Patients

(2009) Pedro A. Andrade Filho et al.   JOURNAL OF IMMUNOTHERAPY

Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists

(2009) Svetlana Hamm et al.   Journal of Immunotoxicology

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

(2009) James A Bonner et al.   LANCET ONCOLOGY

Recognition of viral single-stranded RNA by Toll-like receptors☆

(2008) S DIEBOLD   ADVANCED DRUG DELIVERY REVIEWS

T Regulatory Type 1 Cells in Squamous Cell Carcinoma of the Head and Neck: Mechanisms of Suppression and Expansion in Advanced Disease

(2008) C. Bergmann et al.   CLINICAL CANCER RESEARCH

An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma

(2008) R. Dummer et al.   CLINICAL CANCER RESEARCH

TLR7 and TLR8 as targets in cancer therapy

(2008) M P Schön et al.   ONCOGENE

The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy

(2008) E. L. J. M. Smits et al.   ONCOLOGIST